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Practice Points 31 
1. While pain can have psychological effects on persons with multiple sclerosis (PwMS), there is 32 
limited research on behavioral treatments. 33 
2. PwMS who underwent 12 weeks of a cognitive-behavioral therapy (CBT) or educational program 34 
were very satisfied with their treatment and reported largely meeting their behavioral goals. 35 
3. Participation in either treatment resulted in improvements in pain severity, pain interference, 36 
and emotional well-being, suggesting that a non-pharmacological treatment for pain may be 37 
beneficial for PwMS.   38 
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Abstract 39 
 40 
Background: Pain is a common and often debilitating symptom among persons with multiple sclerosis 41 
(PwMS). Besides interfering with daily functioning, pain in MS is associated with higher levels of 42 
depression and anxiety. While cognitive-behavioral therapy (CBT) for pain has been found to be an 43 
effective treatment in other populations, there has been a dearth of research in PwMS.  44 
Methods: PwMS with at least moderate pain severity (N = 20) were randomly assigned to one of two 45 
groups: CBT plus standard care (CBT/SC) or MS-related education plus standard care (ED/SC), each of 46 
which met for 12 sessions. Changes in pain severity, pain interference, and depressive symptom severity 47 
from baseline to the 15 week follow-up were assessed using a 2x2 factorial design. Participants also 48 
rated their satisfaction with their treatment and accomplishment of personally meaningful behavioral 49 
goals. 50 
Results: Both treatment groups rated their treatment satisfaction as very high and their behavioral goals 51 
as largely met, although only the CBT/SC group’s mean goal accomplishment ratings represented 52 
significant improvement. While there were no significant differences between groups post-treatment on 53 
the three primary outcomes, there was an overall improvement over time for pain severity, pain 54 
interference, and depressive symptom severity.  55 
Conclusions: CBT or education-based programs may be helpful adjunctive treatments for PwMS 56 
experiencing pain.  57 
 58 
 59 
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Introduction 61 
Among persons with multiple sclerosis (PwMS), pain is a common and often severe symptom (1, 2). 62 
Pain may be associated with central nervous system damage, inflammation, treatment side effects, or 63 
an unrelated disease process (e.g., arthritis) (3). Over 88% of PwMS experience pain in more than one 64 
bodily area, with the average being over six distinct pain locations (4). MS-related pain can be acute, 65 
though it often becomes chronic, negatively affecting physical and emotional functioning (3, 5, 6). In a 66 
longitudinal study of chronic pain among PwMS, a significant deterioration in quality of life was noted at 67 
the 10-year follow-up (7). While MS alone can result in functional difficulties, the presence of pain can 68 
contribute to further impairment, such as interference with employment and engagement in 69 
recreational activities (5, 8). Psychological well-being can also be influenced, as PwMS with greater pain 70 
severity tend to endorse higher levels of depressive symptom severity and anxiety (9), with both of the 71 
latter conditions having a prevalence rate of over 20% among PwMS (10).  72 
Despite the prevalence and functional implications of MS-related pain, adequate treatment and 73 
management remain an ongoing issue. Medications are typically the most common treatment, ranging 74 
from over-the-counter drugs to prescription opioids (3, 8). However, medications have limitations 75 
including decreased effectiveness over time and increasing complexity from polypharmacy (8). In 76 
addition, long-term and high dose opioid therapy carries several safety risks, including addiction (11). 77 
Another option is psychotherapeutic interventions, such as cognitive-behavioral therapy (CBT), which 78 
target factors that may be perpetuating persons’ pain experience (6). CBT has been previously used with 79 
success with PwMS for fatigue (12) and depression (13). While CBT has been shown to be an effective 80 
treatment in the general chronic pain population (14), it is still an under-utilized treatment in MS. In a 81 
recent survey of MS providers, only 26% indicated that they refer patients endorsing pain to a clinical 82 
health psychologist (15). Part of the reason for low referral rates may be the limited research. 83 
Psychotherapy for pain in MS has been studied as part of an interdisciplinary treatment program and 84 
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certain strategies, such as cognitive restructuring and self-hypnosis, have been explored with beneficial 85 
results (16, 17). However, to date there has not been a randomized clinical trial of CBT for MS-related 86 
pain.  87 
This study aimed to examine the benefits of CBT for MS-related pain, compared to a contact 88 
matched educational control group (ED). It was hypothesized that PwMS in the CBT group, relative to 89 
those receiving ED, would demonstrate significant improvements in pain severity, with secondary 90 
improvements in pain interference and depressive symptom severity. In addition, treatment satisfaction 91 
and accomplishment of personalized and meaningful behavioral goals were examined.  92 
 93 
Methods 94 
Participants 95 
Criteria for inclusion were a confirmed diagnosis of MS with at least three months of MS-related 96 
pain (e.g., neuropathic pain, pain related to muscle spasms, neuralgias) of at least moderate intensity, 97 
defined as a score of four or greater on the 0 (no pain) to 10 (worst pain imaginable) Numeric Rating 98 
Scale (NRS) (18). There was at least one study neurologist at each study site with specific expertise in MS 99 
management who reviewed potential participants’ electronic health records (EHR) to confirm that 1) 100 
reported pain was directly related (e.g., pain associated with optic neuritis) or indirectly related (e.g., 101 
pain due to muscle contractions) to MS (19); 2) documentation of “optimal pharmacological 102 
management” of MS-related pain was present; and 3) appropriate pharmaceutical interventions were 103 
currently being used. Optimized pharmacological management of MS-related pain was based on the 104 
judgment of a study neurologist and review of available EHR of use of analgesic medications for 105 
musculoskeletal and neuropathic pain, including non-steroids, topicals, opioids, antidepressants, and 106 
anticonvulsants and evidence of benefit and avoidance of side effects, harms, and misuse. The third 107 
aforementioned criterion was applied because of the expectation that psychological and/or educational 108 
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interventions would most often be employed in the context of optimized pharmacological management 109 
of pain. Persons with life threatening or acute physical illnesses (e.g., cancer, end stage renal disease), 110 
current alcohol or substance abuse or dependence (defined as active use within the past three months), 111 
current psychosis, suicidal and/or homicidal ideation as noted in medical progress notes or inpatient 112 
psychiatric hospitalization within the past three months, and persons with pending surgical or 113 
interventional pain management procedures were excluded. PwMS with physical disabilities (e.g., 114 
severe dysarthria) or profound cognitive impairments that would have impeded successful participation 115 
in the treatment sessions were also excluded. If persons had two or more documented exacerbations 116 
(i.e., an event requiring a change in medication type or dose to manage new symptoms and/or clinically 117 
significant increased symptom severity) during the past year and/or experienced an exacerbation within 118 
24 hours of enrollment, they were excluded until they completed one month of appropriate treatment 119 
or were three months post-exacerbation. 120 
Participants were recruited from the greater Yale-New Haven community (New Haven, Connecticut), 121 
VA Connecticut Healthcare System (VACHS) (West Haven, Connecticut), VA Boston Healthcare System 122 
(VABHS) (Boston, Massachusetts), and Griffin Hospital (Derby, Connecticut), as well as through the 123 
National MS and Connecticut MS Societies. Potential participants identified via the VACHS and Yale MS 124 
Center were sent opt-in letters describing the study and eligibility criteria and inviting their participation.  125 
A total of 251 potentially eligible patients were identified via these recruitment methods (Figure 1).  126 
Following EHR review by the study psychologist and neurologist (described below), 186 persons were 127 
found not to be eligible. An additional 42 persons were unable to be contacted or had travel difficulties, 128 
while three were not interested in the study. The remaining 20 participants completed the baseline 129 
assessments and were randomized, using SAS version 8.2 random allocation codes, in equal numbers 130 
between the two conditions. All participants continued their usual or standard care (SC) for MS, pain, 131 
and other comorbid conditions.  132 
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  133 
Procedures 134 
Potential participants were screened for eligibility by both a study psychologist and neurologist by a 135 
review of available EHRs. Eligible participants were scheduled for an in-person session with a study 136 
research assistant during which eligibility was confirmed and signature informed consent was obtained.  137 
Sociodemographic and pain- (e.g., pain locations, pain duration) and MS-descriptive data (e.g., MS 138 
subtype and duration) were collected, and pain-relevant self-report questionnaires described below 139 
were completed. Given the literature on MS’ effects on cognitive abilities (20), participants met with a 140 
study clinical neuropsychologist or a supervised psychology technician for a brief neuropsychological 141 
examination, during which time they completed the MS Functional Composite (MSFC).   142 
Participants who completed all baseline evaluations were randomly assigned to receive either 143 
CBT/SC or ED/SC. Following completion of treatment, participants completed immediate post-treatment 144 
evaluations with a study research assistant who was not blind to intervention condition. Data were 145 
collected via the mail or during an in-person visit with the research assistant. Although there was a 146 
baseline appointment and 12 treatment sessions, there was a window of 15 weeks from collection of 147 
the baseline data to collection of the immediate post-treatment data to permit flexibility in scheduling 148 
sessions and to accommodate significant symptom exacerbations and associated delays in treatment 149 
delivery. 150 
Participants were not compensated for their participation in the study sessions; however, they 151 
were eligible for compensation for their participation in the baseline evaluation and each of the four 152 
follow-up evaluations, for a possible total of $225. The procedures and protocol were approved by the 153 
VACHS, VABHS, and Yale University School of Medicine institutional review boards (IRB#RK0031). 154 
 155 
Study Treatments 156 
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Treatments (CBT/SC and ED/SC) involved 12 sessions, including seven, 60-minute, outpatient, 157 
individual sessions and five, 30-minute individual telephone sessions. Both treatment arms were 158 
delivered by clinical health psychologists with training in care of PwMS and delivering CBT for chronic 159 
pain. Psychologists followed treatment manuals developed for each of the two conditions. The same 160 
psychologists delivered both interventions.    161 
 162 
CBT plus Standard Care (CBT/SC) 163 
Psychologists followed a previously developed treatment protocol (21) that was revised to be 164 
specific to MS-related pain. The protocol also incorporated motivational interviewing strategies to 165 
encourage treatment engagement and adherence to therapist recommendations for pain coping skill 166 
practice. Treatment was tailored and paced according to participant interests, prior knowledge, and 167 
learning capacity. Components of CBT treatment included 1) identification of idiosyncratic beliefs about 168 
pain and pain treatment; 2) instruction in cognitive (e.g., distraction) and behavioral (e.g., activity 169 
pacing) skills; and 3) consolidation of cognitive and behavioral skills through activities such as role-170 
playing. As a method to reinforce material presented during the session, each participant collaborated 171 
with the psychologist to develop intersession behavioral goals and plans for using pain coping skill 172 
practice in the form of “homework.” This allowed psychologists to provide corrective feedback. During 173 
telephone sessions the therapists emphasized adherence to behavioral goal accomplishment, reviewed 174 
prior materials, and presented new didactic material. 175 
 176 
MS-related Education plus Standard Care (ED/SC) 177 
An ED/SC control group was chosen instead of a SC-only group in order to control for non-specific 178 
factors that might contribute to outcomes, such as attending treatment sessions and having personal 179 
contact with a health professional. Furthermore, education about MS-related symptoms is often 180 
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encouraged as an adjunct to routine medical care (22). The National MS Society Sourcebook1 was used 181 
as a therapist manual and for participant handouts. Topics for the 12 sessions include information on MS 182 
etiology, diagnosis and prognosis, pain in MS, medications for symptom management, disease modifying 183 
medications, alternative therapies, rehabilitation, exercise, lifestyle issues, alcohol, and smoking, 184 
preventive health, adapting the home and assistive devices, and caregiver support. Topics that were 185 
psychological in nature, such as the emotional aspects of MS section of the sourcebook, were excluded. 186 
In order to make the two treatment arms equivalent, time was spent with participants creating weekly 187 
behavioral goals corresponding to those developed in CBT as well as discussing the implications of the 188 
content covered in session. The discussions were unstructured and no specific skills were covered. 189 
 190 
Standard Care 191 
In both conditions, participants continued to receive routine care of their MS and MS-related 192 
symptoms, including pain management, by their current healthcare providers (not research staff). 193 
Standard of care usually consisted of being seen in an outpatient specialty clinic with a neurologist who 194 
collaborated with other clinicians to care for patients in all stages of the disease. No efforts were made 195 
to influence management of MS, MS-related pain, or other health concerns. Medication use, including 196 
changes in medication, self-reported adherence, and extra doses of pain medications, however, were 197 
monitored by participant completion of a weekly questionnaire. Eight of the CBT/SC and seven of the 198 
ED/SC participants had changes in the medications.  199 
 200 
Measures 201 
Outcomes  202 
                                                            
1 https://secure.nationalmssociety.org/site/SPageServer/?pagename=HOM_LIB_sourcebook 
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Outcome measures (Figure 2) were selected to represent core outcome domains for clinical trials for 203 
chronic pain as recommended by the Initiative on Methods, Measures and Pain Assessment in Clinical 204 
Trials (IMMPACT) (23). Three measures were used to assess participants’ pain severity: the NRS (24), 205 
West Haven-Yale Multidimensional Pain Inventory (WHYMPI) (25), and McGill Pain Questionnaire (26). 206 
In order to minimize type I errors due to multiple comparisons, a Pain Severity Composite Score was 207 
created using the NRS, WHYMPI Pain Severity subscale, and McGill Evaluative subscale, which had 208 
moderately high internal consistency (α = .77). Participants’ perceived level of pain interference with 209 
social role functioning (i.e., day-to-day activities, work, recreational and other social activities, family-210 
related activities, and household chores) was also measured using the WHYMPI Interference subscale. 211 
Depressive symptom severity was measured using the Beck Depression Inventory (BDI-1) (27).  212 
 213 
Physical and Cognitive Measures 214 
Level of disability was assessed using the MSFC, a composite score that includes measures of 215 
cognitive processing speed (Paced Auditory Serial Addition Test; PASAT), fine motor functioning (9-Hole 216 
Peg Test; 9-HPT), and ambulation (25-foot walk) (28). The MSFC was calculated using the equation and 217 
National MS Society normative data that were provided in the manual (29). 218 
 219 
Treatment Goals, Credibility, and Satisfaction 220 
Prior to receiving the interventions, all participants were asked to identify up to five S.M.A.R.T 221 
(specific, measurable, achievable, results-focused, and time-bound) treatment goals. Post-treatment, 222 
they rated their level of accomplishment on a scale of -2 (100% decline) to 2 (100% improvement) (30). 223 
During their first session, participants rated the credibility and expectancy for improvement for their 224 
assigned treatment (31). At week 15, participants completed the Pain Outcomes Questionnaire-Pain 225 
Treatment Satisfaction Scale (PTSS), in which they rated their level of satisfaction with the overall 226 
11 
 
treatment, staff warmth and skills, ease of getting appointments, and recommendation of the treatment 227 
to others on a scale of 0 (no satisfaction) to 10 (complete satisfaction). A total score was generated by 228 
averaging the sum of the five questions (32). 229 
 230 
Statistical Analyses 231 
Analyses were approached as intent-to-treat. Missing values analysis was conducted (χ2(67) = 12.54, 232 
p = 1.00), which justified the use of the expectation maximization (EM) method to impute values for 233 
missing outcome data points. Differences between the two treatment groups’ demographic and disease-234 
related characteristics were assessed using t-tests for continuous data and chi-square for categorical 235 
data. Changes on the outcome measures were evaluated using a 2 (CBT/SC and ED/SC) x 2 (pre- and 236 
post-treatment) factorial design. Treatment credibility, treatment satisfaction, and behavioral goal 237 
accomplishment between the two conditions were compared using t-tests.  238 
 239 
Results 240 
Demographics 241 
The overall sample (Table 1) was largely comprised of persons with relapsing remitting MS (70%), 242 
with an average age of 52.60 (SD = 10.95) and 15.05 years (SD = 2.14) of education. There was a higher 243 
ratio of men to women (3:2), and 75% of the sample was Caucasian. Participants reported that they had 244 
been diagnosed with MS for 13.25 (SD = 10.23) years and had been experiencing pain for 13.23 (SD = 245 
13.00) years. The average level of disability on the MSFC was -1.17 (SD = 2.28). Participants reported an 246 
average of 4.25 (SD = 1.45) pain locations, most commonly in the legs/feet (95%) and lower back (80%). 247 
On average, participants attended ten (SD = 3.92) sessions in the CBT/SC group and eight (SD = 5.42) 248 
sessions in the ED/SC group. There were no differences between the two treatment groups at baseline 249 
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in terms of age, gender, race/ethnicity, MS subtype, MSFC, MS duration, pain duration, or pain 250 
locations. During the study period, no adverse events or serious adverse events were reported. 251 
 252 
Pain Severity and Interference 253 
At baseline, there was no difference between the CBT/SC and ED/SC groups in terms of the 254 
composite pain severity score (t(18) = -0.30, p = .767).  There was a significant effect for Time (F(1,18) =  255 
4.61, p = .046), indicating a beneficial treatment effect on pain severity, but the Time x Treatment 256 
interaction was not statistically significant (F(1,18) = 0.61, p = .444).    257 
The CBT/SC group reported lower pain interference than the ED/SC group at baseline, which was a 258 
significant difference (t(18) = -3.42, p = .003). As with pain severity, there was a significant effect from 259 
Time (F(1,18) = 4.63, p = .045), with an overall decrease in pain interference at the 15 week follow-up. 260 
Time x Treatment effects were not statistically significant (F(1,18) = 0.06, p = .813).  261 
 262 
Depressive Symptoms 263 
Participants in the CBT/SC condition, relative to those in the ED/SC condition, reported lower 264 
depressive symptom severity in the CBT/SC group at baseline compared to the ED/SC group, but this 265 
difference did not reach significance (t(18) = -2.04, p = .056). Similar to both pain outcomes, a 266 
statistically significant effect of Time was observed (F(1,18) = 5.79, p = .027) indicating a significant 267 
decrease in depressive symptom severity as a function of treatment, and the Time x Treatment effect 268 
was not statistically significant (F(1,18) = 1.24, p = .280).    269 
 270 
Treatment Credibility and Satisfaction 271 
The CBT/SC group’s ratings of their treatment credibility and expectancy for improvement was 272 
higher than those of the ED/SC group, although the difference did not reach significance (t(15) = 1.52, p 273 
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= .150). Both groups’ treatment total satisfaction ratings were high. The difference between the two 274 
groups was not significantly different (t(16) = -0.04, p = .967).  275 
 276 
Goal Accomplishment 277 
Mean behavioral goal accomplishment ratings for the CBT/SC group average was significantly 278 
different from zero (1.27 ± 0.55, 95% CI: 0.87, 1.66), indicating significant improvement. In contrast, the 279 
ED/SC group’s mean goal accomplishment rating was not significantly different from zero (0.65 ± 1.20, 280 
95% CI: -0.35, 1.65). The mean goal accomplishment ratings were not significantly different between the 281 
two groups (t(9.37) = 1.36, p = .207).  282 
 283 
Discussion 284 
More than half of PwMS endorse having pain, which can affect their daily functioning, emotional 285 
well-being, and quality of life (2, 5-9). While pharmacological treatments are most often used (3, 8), they 286 
do not target the cognitive, behavioral, and psychosocial factors that may be contributing to the pain 287 
experience (6). The current study investigated whether CBT, an effective intervention in the general 288 
chronic pain population (14), could be beneficial for MS-related pain. MS-related education was 289 
employed as a comparison condition in this randomized controlled trial. 290 
Overall, both the CBT/SC and ED/SC groups were observed to improve as a function of treatment on 291 
important outcome measures, namely pain severity, pain interference, and depressive symptom 292 
severity. Contrary to our stated hypothesis, there was no evidence that participants in the CBT/SC 293 
condition accrued greater benefit in terms of any of these outcomes relative to participants in the ED/SC 294 
condition. Similarly, participants in both treatment conditions also endorsed very high levels of 295 
treatment satisfaction, and no difference between the two conditions in these ratings was observed.  296 
Finally, both groups largely reported that they completed their treatment goals. Although no significant 297 
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differences in goal accomplishment were noted between participants in the two conditions, only the 298 
CBT/SC group’s ratings were significantly different from zero, suggesting clinically meaningful 299 
achievement of personally meaningful goals. As the first clinical trial of CBT for the treatment of pain 300 
among PwMS, these findings are encouraging, albeit preliminary. At the same time, the observed 301 
benefits of a structured and intensive educational condition and the lack of significant incremental 302 
benefits of CBT relative to the education condition suggest that either approach may be beneficial for 303 
the management of pain among PwMS.   304 
Since the measure of pain severity was a composite of three standardized measures of this 305 
construct, there are no published guidelines for interpreting clinically significant change. For the 306 
measure of pain interference, the observed mean reduction across both interventions (0.61) was 307 
consistent with IMMPACT recommendations for determining a clinically significant change (33). 308 
Similarly, for the measure of depressive symptom severity, Vlaeyen and colleagues (34) recommended 309 
that a mean reduction of four points and a final score of 10 or less could be considered evidence of 310 
clinically meaningful improvement. In the current study, the observed reduction of 3.77 was slightly 311 
below the recommendations for a clinically significant improvement while the mean score after 312 
treatment was below 10. Together, the observed data could be interpreted as being consistent with 313 
clinically meaningful improvements in at least pain interference, and possibly depressive symptoms and 314 
pain severity. As such, physicians and other providers may consider referring PwMS experiencing pain to 315 
one of these interventions as part of a comprehensive pain management strategy. 316 
The findings of this study should be interpreted with caution. Of particular relevance is the fact that 317 
the study is substantially underpowered to detect effects of the two treatment conditions and especially 318 
between group effects. Despite extensive recruitment efforts, a relatively small number of PwMS were 319 
referred or otherwise conveyed interest in participating in the study, and of these, less than 10% of 320 
persons who were screened met eligibility criteria and provided consent to participate. Among a range 321 
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of factors apparently contributing to the low rates of engagement observed, the inability of the study 322 
neurologist to confirm the diagnosis of MS was particularly noted. Failure to meet a minimal threshold 323 
for pain severity, sometimes due to apparent successful medication management, was also a significant 324 
limiting factor. Ultimately, these PwMS were most often Caucasian men, well-educated, and relatively 325 
high functioning. These observations may suggest a recruitment bias that undermines generalization to 326 
women, minorities, less well educated, and more impaired PwMS.  327 
Although demographics and pain severity were controlled during the randomization process, the 328 
CBT group had lower levels of pain interference at baseline, which may have influenced their response 329 
to the treatment. Prior research has suggested that higher levels of pain interference at baseline in 330 
clinical trials of CBT for chronic pain may be associated with poorer rates of treatment completion (35). 331 
For some potentially eligible and interested PwMS, barriers to accessing care such as difficulties with 332 
mobility and transportation were salient factors that may have precluded weekly on-site attendance. 333 
Future research may explore if other intervention delivery methods may increase attendance levels, 334 
such as telehealth, which has shown promising results in physical rehabilitation (36), medication 335 
adherence (37), and self-management (38) among PwMS. In addition, while pain can be a severe and 336 
intrusive symptom for PwMS (1, 5, 8), it may not be prioritized in relation to other MS symptoms. 337 
Persons who participated in this study endorsed similar pain and MS durations, potentially suggesting 338 
that if pain is a significant portion of their MS presentation, they may be more likely to participate in 339 
MS-related pain research. As such, future studies may examine the role of pain’s intrusiveness to 340 
persons’ overall experience of MS-related impairment and symptoms. 341 
The findings suggest that PwMS who have pain were very satisfied and largely completed their 342 
treatment goals after completion of a CBT or educational program. Given the overall improvements in 343 
aspects of pain and emotional well-being, further investigation of non-pharmacological interventions for 344 
MS-related pain is warranted.  345 
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Figure Legends 454 
 455 
Figure 1: CONSORT flow diagram 456 
 457 
Figure 2: Outcomes measures at baseline through follow-up for both groups. 458 
BDI-1: Beck Depression Inventory; NRS: Numeric Rating Scale; PTSS: Pain Treatment Satisfaction Scale; 459 
WHYMPI: West Haven-Yale Multidimensional Pain Inventory 460 
  461 
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Tables 462 
 463 
Table 1: Participants’ demographic and outcome information 464 
CBT/SC: Cognitive behavioral therapy plus standard care; ED/SC: Education plus standard care; MSFC: 465 
MS Functional Composite; PTSS: Pain Treatment Satisfaction Scale; PPMS: primary progressive MS; 466 
RPMS: relapsing progressive MS; RRMS: relapsing remitting MS 467 
 468 
 Total  
(N=20) 
CBT/SC 
(N=10) 
ED/SC 
(N=10) 
Age 52.60 ± 10.95 52.20 ± 9.61 53.00 ± 12.66 
Education (Years) 15.05 ± 2.14 15.50 ± 2.15 14.60 ± 2.12 
Gender Females: 8 
Males: 12 
Females: 4 
Males: 6 
Females: 4 
Males: 6 
Race Caucasian: 15 
African-American: 2 
Mixed: 2 
Other: 1 
Caucasian: 7 
African-American: 1 
Mixed: 1 
Other: 1 
Caucasian: 8 
African-American: 1 
Mixed: 1 
MS Type RRMS: 14 
RPMS: 4 
PPMS: 2 
RRMS: 8 
RPMS: 1 
PPMS: 1 
RRMS: 6 
RPMS: 3 
PPMS: 1 
MS Duration (Years) 13.25 ± 10.23 12.60 ± 7.40 13.90 ± 12.86 
MSFC -1.17 ± 2.28 -1.71 ± 2.27 -1.83 ± 2.40 
Pain Duration (Years) 13.23 ± 13.00 11.30 ± 10.24 15.15 ± 15.61 
Number of Pain Locations 4.25 ± 1.45 3.80 ± 1.03 4.70 ± 1.70 
Pain Locations Arms/Hands: 60% 
Legs/Feet: 95% 
Upper Back: 45% 
Lower Back: 80% 
Head/Facial: 50% 
Neck: 55% 
Other: 40% 
Arms/Hands: 50% 
Legs/Feet: 90% 
Upper Back: 50% 
Lower Back: 70% 
Head/Facial: 30% 
Neck: 60% 
Other: 30% 
Arms/Hands: 70% 
Legs/Feet: 100% 
Upper Back: 40% 
Lower Back: 90% 
Head/Facial: 70% 
Neck: 50% 
Other: 50% 
Baseline Pain Severity 4.19 ± 1.21 4.11 ± 1.38 4.28 ± 1.08 
Post-Treatment Pain Severity 3.67 ± 1.03 3.78 ± 0.94 3.57 ± 1.40 
Baseline Pain Interference 3.77 ± 1.42 2.90 ± 1.31 4.64 ± 0.93 
Post-Treatment Pain Interference 3.16 ± 1.57 2.36 ± 1.33 3.96 ± 1.42 
Baseline Depression 13.38 ± 7.04 10.37 ± 5.72 16.32 ± 7.23 
Post-Treatment Depression 9.61 ± 6.89 8.36 ± 5.56 10.85 ± 8.12 
Treatment Credibility 40.41 ± 7.09 42.78 ± 7.81 37.75 ± 5.47 
PTSS Total Score 9.59 ± 0.63 9.56 ± 0.71 9.63 ± 0.57 
 469 
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Figure 1: CONSORT flow diagram 
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Figure 2: Outcomes measures at baseline through follow-up for both groups. 
BDI-1: Beck Depression Inventory; NRS: Numeric Rating Scale; PTSS: Pain Treatment Satisfaction Scale; 
WHYMPI: West Haven-Yale Multidimensional Pain Inventory 
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